ClinicalTrials.gg
Active, not recruitingNCT07433166CTS-PDUpdated Nov 19, 2026

Ultrasound Evaluation in Carpal Tunnel Syndrome

An observational study in Carpal Tunnel Syndrome (CTS), sponsored by SB Istanbul Education and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by SB Istanbul Education and Research Hospital · Observational

How we know

Updated Nov 19, 2026Now Active, not recruitingFirst site in Turkey (Türkiye)+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.

Planned enrollment
18th of 48
100 · median 84
Started
2026
with 19 others
Observational
48 of 130
15 open now
Primary completion
2026-12
later than 28 of 40 live
Registered
113th of 130
by date

Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 18th largest by planned enrollment of the 48 observational ones that give a count, is one of 20 that started in 2026, is one of 48 observational ones, reaches primary completion later than 28 of the 40 other live ones, and was the 113th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Carpal Tunnel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This prospective cohort study aims to evaluate median nerve cross-sectional area and intraneural vascularity using power Doppler ultrasonography in patients with carpal tunnel syndrome. Ultrasonographic findings will be compared between diabetic and non-diabetic patients. Clinical severity and electrophysiological findings will be correlated with ultrasonographic parameters.

03

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • carpal tunnel
  • ultrasound
  • power doppler
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Carpal Tunnel Syndrome Patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinically and electrophysiologically confirmed carpal tunnel syndrome
  • symptom duration > 3 months
  • written

Exclusion criteria

Exclusion Criteria:

  • previous wrist surgery
  • cervical radiculopathy
  • inflammatory arthritis
  • pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testDoppler ultrasound

    The predictive power of cross-sectional area and intraneural blood flow measured by ultrasound on surgical outcomes will be tested.

06

What researchers measure

Primary outcomes

  1. Intraneural Vascularity

    Intraneural blood flow will be evaluated using power Doppler ultrasonography at the level of the carpal tunnel inlet. The presence and degree of intraneural vascularity will be graded using a semi-quantitative scoring system: 0 = No detectable intraneural flow 1. = Single vessel signal 2. = Multiple vessel signals 3. = Marked hypervascularity The total score ranges from 0 to 3. Higher scores indicate increased intraneural vascularity.

    Time frame: Baseline

  2. Cross sectional Area

    The cross-sectional area of the median nerve will be measured using ultrasonography at the level of the pisiform bone (carpal tunnel inlet) and proximal to transvers carpal ligament. Measurements will be obtained by tracing the inner border of the hyperechoic epineurium. Values will be recorded in square millimeters (mm²). Higher values indicate greater nerve swelling.

    Time frame: baseline

Secondary outcomes

  1. Boston Carpal Tunnel Questionnaire

    Change in Symptom Severity Score of the Boston Carpal Tunnel Questionnaire The Boston Carpal Tunnel Questionnaire is a patient-reported outcome measure consisting of 11 questions assessing symptom severity. Each item is scored from 1 (no symptoms) to 5 (most severe symptoms). The total score ranges from 11 to 55. Higher scores indicate worse symptom severity.

    Time frame: Baseline, 3th and 6th months

07

Study locations

1 site
  • Istanbul EAH
    Istanbul, Turkey (Türkiye)
08

References and documents

Publications

  • Erickson M, Lawrence M, Lucado A. The role of diagnostic ultrasound in the examination of carpal tunnel syndrome: an update and systematic review. J Hand Ther. 2022 Apr-Jun;35(2):215-225. doi: 10.1016/j.jht.2021.04.014. Epub 2021 Apr 14. PubMed 34261588 ↗

Individual participant data

Plan to share: No — Data sharing is not planned due to patient confidentially and instutional policy

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 7 months is below that.

Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 25, 2026
StartActual
May 20, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 19, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Istanbul EAH · Istanbul, Turkey (Türkiye)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Istanbul EAH · Istanbul, Turkey (Türkiye)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07433166
Lead sponsor
SB Istanbul Education and Research Hospital
Responsible party
Baris Acar (Principal investigator, SB Istanbul Education and Research Hospital) — Principal investigator
First posted
Feb 25, 2026
Start date
May 20, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion